Drug search by name

Acarbose and Liver disease

Result of checking the interaction of drug Acarbose and disease Liver disease for safety when used together.

Check result:

Acarbose <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice. Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day. Therapy with acarbose should be administered cautiously in patients with liver disease. Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter. If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.

References:

Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
"Product Information. Precose (acarbose)." Bayer, West Haven, CT.
Andrade RJ, Lucena MI, Rodriguezmendizabal M "Hepatic injury caused by acarbose." Ann Intern Med 124 (1996): 931
Balfour JA, McTavish D "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs 46 (1993): 1025-54

Acarbose

Generic Name: acarbose

Brand Name: Precose

Synonyms: n.a.

What is Acarbose?